{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:10:34Z","timestamp":1792181434790,"version":"4.4.0"},"reference-count":64,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1080\/14787210.2021.1961579","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T09:04:56Z","timestamp":1627549496000},"page":"267-278","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Antiviral drugs for coronavirus disease 2019 (COVID-19): a systematic review with network meta-analysis"],"prefix":"10.1080","volume":"20","author":[{"given":"George N.","family":"Okoli","sequence":"first","affiliation":[{"name":"University of Manitoba","place":["Winnipeg, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasheda","family":"Rabbani","sequence":"additional","affiliation":[{"name":"University of Manitoba","place":["Winnipeg, Canada"]},{"name":"University of Manitoba","place":["Winnipeg, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amenah","family":"Al-Juboori","sequence":"additional","affiliation":[{"name":"University of Manitoba","place":["Winnipeg, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Copstein","sequence":"additional","affiliation":[{"name":"University of Manitoba","place":["Winnipeg, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Askin","sequence":"additional","affiliation":[{"name":"University of Manitoba","place":["Winnipeg, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Abou-Setta","sequence":"additional","affiliation":[{"name":"University of Manitoba","place":["Winnipeg, Canada"]},{"name":"University of Manitoba","place":["Winnipeg, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"key":"e_1_3_5_2_1","article-title":"The reproductive number of COVID-19 is higher compared to SARS coronavirus","volume":"27","author":"Liu Y","year":"2020","unstructured":"Liu Y, Gayle A, Wilder-Smith A, et al. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med Journal Translated Name Journal of Travel Medicine. 2020 Mar 1;27:taaa021","journal-title":"J Travel Med Journal Translated Name Journal of Travel Medicine."},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.02.060"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30651-4"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.201600"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2020.06.013"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30264-3"},{"issue":"18","key":"e_1_3_5_8_1","first-page":"1775","article-title":"Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy","volume":"323","author":"Onder G","year":"2020","unstructured":"Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. Jama-J Am Med Assoc. 2020 May 12;323(18):1775\u20131776.","journal-title":"Jama-J Am Med Assoc"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007016"},{"key":"e_1_3_5_10_1","first-page":"1","article-title":"An update on current therapeutic drugs treating COVID-19","volume":"11","author":"Wu R","year":"2020","unstructured":"Wu R, Wang L, Kuo HD, et al. An update on current therapeutic drugs treating COVID-19. Curr Pharmacol Rep. 2020;11:1\u201315.","journal-title":"Curr Pharmacol Rep"},{"key":"e_1_3_5_11_1","unstructured":"World Health Organization. WHO R&D blueprint novel coronavirus (nCov) vaccine prioritization for clinical trials 2020 [cited 2021 Jan 12]. Available from: https:\/\/bit.ly\/2MTACxX"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00162-20"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2020.05.001"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki209"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2423-5"},{"key":"e_1_3_5_16_1","first-page":"1813\u20131826","article-title":"Remdesivir for the treatment of Covid-19 - final report","author":"Beigel JH","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020 Oct;383(19):1813\u20131826.","journal-title":"N Engl J Med"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03011-14"},{"key":"e_1_3_5_18_1","unstructured":"World Health Organization. A coordinated global research roadmap: 2019 novel coronavirus2020 [cited 2021 Jan 12]. Available from: https:\/\/bit.ly\/38DNAbz"},{"key":"e_1_3_5_19_1","unstructured":"United States Food and Drug Administration. NDA 214787: cross Discipline Team Leader Division Director and ODE Director Summary Review Maryland USA: United States Food and Drug Administration; 2020 [cited 2020 Oct 23]. Available from: https:\/\/bit.ly\/2TiAYOz"},{"key":"e_1_3_5_20_1","doi-asserted-by":"crossref","unstructured":"WHO Solidarity Trial Consortium Pan H Peto R et al. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. N Engl J Med. 2020;384(6):497-511.","DOI":"10.1056\/NEJMoa2023184"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00894-020-04600-4"},{"key":"e_1_3_5_22_1","first-page":"1","article-title":"Combined drug repurposing and virtual screening strategies with molecular dynamics simulation identified potent inhibitors for SARS-CoV-2 main protease (3CLpro)","author":"Khan A","year":"2020","unstructured":"Khan A, Ali S, Khan M, et al. Combined drug repurposing and virtual screening strategies with molecular dynamics simulation identified potent inhibitors for SARS-CoV-2 main protease (3CLpro). J Biomol Struct Dyn Journal Translated Name Journal of Biomolecular Structure and Dynamics. 2020; 1\u201312.","journal-title":"J Biomol Struct Dyn Journal Translated Name Journal of Biomolecular Structure and Dynamics"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2021.1923799"},{"key":"e_1_3_5_24_1","unstructured":"Higgins J Lasserson T Chandler J et al. Methodological expectations of Cochrane intervention reviews (MECIR). 2016."},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.01.021"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-00694-1"},{"key":"e_1_3_5_28_1","unstructured":"Cochrane COVID-19 Study Register [Internet]. London United Kingdom: The Cochrane Collaboration. 2020 [cited 2020 Aug 10]. Available from: https:\/\/bit.ly\/2TbZssW."},{"key":"e_1_3_5_29_1","unstructured":"COVID-19: global literature on coronavirus disease [Internet]. Geneva Switzerland: The World Health Organization. 2020 [cited 2020 Aug 7]. Available from: https:\/\/bit.ly\/34knI2B."},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30483-7"},{"key":"e_1_3_5_31_1","first-page":"366","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"28","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ-Brit Med J. 2019;28:366.","journal-title":"BMJ-Brit Med J"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212650"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1037"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-019-0829-2"},{"key":"e_1_3_5_35_1","unstructured":"Plummer M. JAGS Version 4.3.0 user manual 2017 [cited 2021 Apr 13]. Available from: https:\/\/bit.ly\/3mOcxqf"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1054"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.7326\/M19-0993"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/1467-9868.00353"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/10618600.1998.10474787"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X13485157"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00049-8"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7304.101"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa241"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2015301"},{"key":"e_1_3_5_48_1","first-page":"11","article-title":"No statistically apparent difference in antiviral effectiveness observed among ribavirin plus interferon-alpha, lopinavir\/ritonavir plus interferon-alpha, and ribavirin plus lopinavir\/ritonavir plus interferon-alpha in patients with mild to moderate coronavirus disease 2019: results of a randomized, open-labeled prospective study","volume":"14","author":"Huang YQ","year":"2020","unstructured":"Huang YQ, Tang SQ, Xu XL, et al. No statistically apparent difference in antiviral effectiveness observed among ribavirin plus interferon-alpha, lopinavir\/ritonavir plus interferon-alpha, and ribavirin plus lopinavir\/ritonavir plus interferon-alpha in patients with mild to moderate coronavirus disease 2019: results of a randomized, open-labeled prospective study. Front Pharmacol. 2020;14:11.","journal-title":"Front Pharmacol"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31042-4"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2020.04.001"},{"key":"e_1_3_5_51_1","first-page":"157","article-title":"Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial","volume":"1","author":"Lou Y","year":"2021","unstructured":"Lou Y, Liu L, Yao HP, et al. Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial. Eur J Pharm Sci. 2021;1:157.","journal-title":"Eur J Pharm Sci"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106903"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa334"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.16349"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31022-9"},{"issue":"10","key":"e_1_3_5_56_1","first-page":"1185","article-title":"Efficacy and safety of triazavirin therapy for coronavirus disease 2019: a pilot randomized controlled trial","volume":"6","author":"Wu X","year":"2020","unstructured":"Wu X, Yu K, Wang Y, et al. Efficacy and safety of triazavirin therapy for coronavirus disease 2019: a pilot randomized controlled trial. Engineering (Beijing). 2020 Oct;6(10):1185\u20131191.","journal-title":"Engineering (Beijing)"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.07.053"},{"key":"e_1_3_5_58_1","article-title":"Drug treatments for covid-19: living systematic review and network meta-analysis","volume":"370","author":"Siemieniuk RAC","year":"2020","unstructured":"Siemieniuk RAC, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ-Brit Med J. 2020Jul;370:m2980.","journal-title":"BMJ-Brit Med J"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243705"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26256"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.200647"},{"key":"e_1_3_5_62_1","unstructured":"World Health Organization. Emergencies preparedness response: SARS-CoV-2 Variants Geneva Switzerland: The World Health Organization; [cited 2021 Mar 9]. Available from: https:\/\/bit.ly\/2OEEMLf"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6803a1"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1086\/650458"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70267-6"}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14787210.2021.1961579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T18:39:06Z","timestamp":1770403146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14787210.2021.1961579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1080\/14787210.2021.1961579"],"URL":"https:\/\/doi.org\/10.1080\/14787210.2021.1961579","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"value":"1478-7210","type":"print"},{"value":"1744-8336","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}